Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Research & Development (2020 - 2025)

Candel Therapeutics' Research & Development history spans 4 years, with the latest figure at $7.3 million for Q4 2023.

  • On a quarterly basis, Research & Development rose 45.98% to $7.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $24.5 million, a 17.89% increase, with the full-year FY2025 number at $14.7 million, down 23.69% from a year prior.
  • Research & Development hit $7.3 million in Q4 2023 for Candel Therapeutics, up from $5.8 million in the prior quarter.
  • Over the last five years, Research & Development for CADL hit a ceiling of $7.3 million in Q4 2023 and a floor of $1.8 million in Q2 2020.
  • Historically, Research & Development has averaged $4.5 million across 4 years, with a median of $5.0 million in 2022.
  • Biggest five-year swings in Research & Development: surged 190.4% in 2021 and later grew 0.96% in 2023.
  • Tracing CADL's Research & Development over 4 years: stood at $3.5 million in 2020, then grew by 9.05% to $3.9 million in 2021, then increased by 29.01% to $5.0 million in 2022, then soared by 45.98% to $7.3 million in 2023.
  • Business Quant data shows Research & Development for CADL at $7.3 million in Q4 2023, $5.8 million in Q3 2023, and $5.9 million in Q2 2023.